We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+12.38%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$4.12B
AUM Growth
+$545M
Cap. Flow
+$53M
Cap. Flow %
1.29%
Top 10 Hldgs %
48.24%
Holding
158
New
26
Increased
23
Reduced
71
Closed
24

Top Buys

Rank Stock Value
1
KLRS
Kalaris Therapeutics
KLRS
+$69M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$68.4M
3
BEKE icon
KE Holdings
BEKE
+$43.5M
4
IGMS
IGM Biosciences
IGMS
+$40.8M
5
ITOS
iTeos Therapeutics
ITOS
+$29.4M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$42.9M
2
PYPL icon
PayPal
PYPL
+$34.8M
3
AVTR icon
Avantor
AVTR
+$34M
4
ARGX icon
argenx
ARGX
+$30.2M
5
Z icon
Zillow
Z
+$22.1M

Sector Composition

Rank Sector Weight
1 Healthcare 57.99%
2 Miscellaneous 26.49%
3 Consumer Discretionary 10.25%
4 Technology 2.5%
5 Real Estate 1.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TSM icon
151
CALL
TSMC
TSM
$2.17T
– –
-100,000
Closed -$5.68M
VNET
152
VNET Group
VNET
$1.75B
– –
-583,000
Closed -$13.9M
TCDA
153
DELISTED
Tricida, Inc. Common Stock
TCDA
– –
-285,000
Closed -$7.83M
CLVS
154
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-500,000
Closed -$3.38M
EPZM
155
CALL
DELISTED
Epizyme, Inc
EPZM
– –
-1,000,000
Closed -$16.1M
ALXN
156
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-500,000
Closed -$56.1M
IMMU
157
DELISTED
Immunomedics Inc
IMMU
– –
-230,838
Closed -$8.18M
PRNB
158
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
– –
-200,000
Closed -$12M
3 4 5 6
7

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q3 2020 Portfolio in Review

As of Q3 2020, Artal Group held 158 positions worth $4.12B, up 15% from $3.57B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Artal Group's Q3 2020 filing shows 26 new, 23 increased, 71 reduced and 24 closed positions. Its largest new stake was Kalaris Therapeutics: 101,016 shares worth $63.9M. The largest sale was Blueprint Medicines, an estimated $42.9M.

By sector, the portfolio is most concentrated in Healthcare at 58% of assets, down from 62% a quarter earlier, followed by Miscellaneous and Consumer Discretionary.

  • Artal Group's largest Q3 2020 buy was Kalaris Therapeutics: 101,016 shares worth $63.9M.
  • Artal Group added most to Agenus in Q3 2020, an estimated $16.1M increase.
  • Artal Group's biggest Q3 2020 reduction was argenx, cutting an estimated $30.2M.
  • Artal Group fully exited Blueprint Medicines in Q3 2020, selling an estimated $42.9M.
  • Artal Group's ten largest holdings make up 48% of its $4.12B portfolio in Q3 2020.
  • Artal Group opened 26 new positions and closed 24 in Q3 2020.
  • Artal Group's portfolio value rose 15% quarter-over-quarter to $4.12B.

Based on Artal Group's 13F filing for Q3 2020, filed 13 Nov 2020.